EGFR and non-small cell lung carcinoma: We demonstrate that loss of CAMSAP3 confers resistance to osimertinib through EGFR-independent pathways in NSCLC, though the precise molecular mechanisms underlying CAMSAP3-mediated acquired resistance require further exploration using omics approaches.